Last reviewed · How we verify
ranibizumab PRN
Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and vascular permeability in the eye.
Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and vascular permeability in the eye. Used for Neovascular (wet) age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion (branch and central).
At a glance
| Generic name | ranibizumab PRN |
|---|---|
| Also known as | Lucentis |
| Sponsor | Seoul National University Hospital |
| Drug class | VEGF-A inhibitor monoclonal antibody fragment |
| Target | VEGF-A (Vascular Endothelial Growth Factor A) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Ranibizumab blocks VEGF-A, a key driver of pathological neovascularization and increased vascular permeability in retinal diseases. By neutralizing VEGF-A, it reduces fluid leakage, prevents abnormal vessel formation, and slows disease progression. The PRN (pro re nata/as-needed) dosing regimen involves monthly monitoring with injections administered only when retreatment criteria are met.
Approved indications
- Neovascular (wet) age-related macular degeneration
- Diabetic macular edema
- Retinal vein occlusion (branch and central)
- Myopic choroidal neovascularization
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular pressure elevation
- Endophthalmitis
- Retinal detachment
Key clinical trials
- Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (PHASE3)
- A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD) (PHASE3)
- A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD (PHASE3)
- Ranibizumab and Reduced Fluence PDT for AMD (PHASE2)
- Stereotactic Radiotherapy for Wet AMD (STAR) (PHASE3)
- The Treatment Burden of Myopic Choroidal Neovascularization
- AAVCAGsCD59 for the Treatment of Wet AMD (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ranibizumab PRN CI brief — competitive landscape report
- ranibizumab PRN updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI